Last reviewed · How we verify
Treatment C (placebo)
Placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and physiological expectation.
Placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and physiological expectation. Used for Used as control comparator in clinical trials across all therapeutic areas.
At a glance
| Generic name | Treatment C (placebo) |
|---|---|
| Also known as | IV Placebo, Placebo tablets |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials. Any observed effects result from the placebo effect—a psychobiological phenomenon where patient expectations, clinical context, and the ritual of treatment activation neural pathways associated with symptom relief. Placebos are essential for establishing the true efficacy of active drugs by comparison.
Approved indications
- Used as control comparator in clinical trials across all therapeutic areas
Common side effects
- Nocebo effects (adverse events attributed to placebo expectation)
Key clinical trials
- The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists (PHASE1)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia (PHASE1)
- A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE2, PHASE3)
- In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors (NA)
- A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy (PHASE3)
- HEALEY ALS Platform Trial - Master Protocol (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment C (placebo) CI brief — competitive landscape report
- Treatment C (placebo) updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI